Selpercatinib

103 interactions 8 explained in plain English

Also sold as: Retevmo Retevmo®

About Selpercatinib

Selpercatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) in adults that has spread to nearby tissues or other parts of the body. It is also used to treat a certain type of thyroid cancer in adults and children 12 years of age and older that has spread to other parts of the body. Selpercatinib… Read the full Selpercatinib drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jun 30, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Ketoconazole Topical Oxaliplatin Injection Axitinib Felbamate Eribulin Injection Levofloxacin Injection

1 Contraindicated 99 Major 3 Moderate

All (103) Contraindicated (1) Major (99) Moderate (3)

Major

Selpercatinib Dolasetron Injection Anzemet Increased risk of QT interval prolongation Details Selpercatinib Encorafenib Braftovi Increased risk of QT interval prolongation Details Selpercatinib Entrectinib Rozlytrek Increased substrate exposure, an increased risk of adverse reaction and an increased risk of QT interval prolongation Details Selpercatinib Eribulin Injection Halaven Increased risk of QT interval prolongation Details Selpercatinib Esomeprazole Nexium Reduced selpercatinib exposure and reduced anti-tumor activity Details Selpercatinib Esomeprazole Injection Nexium Reduced selpercatinib exposure and reduced anti-tumor activity Details Selpercatinib Everolimus Afinitor Increased CYP3A and P-gp substrate with NTI exposure and an increased risk of CYP3A and P-gp with NTI-related adverse events Details Selpercatinib Famotidine Calmicid Reduced selpercatinib exposure, reduced anti-tumor activity and an increased risk of QT interval prolongation Details Selpercatinib Famotidine Injection Calmicid Reduced selpercatinib exposure, reduced anti-tumor activity and an increased risk of QT interval prolongation Details Selpercatinib Felbamate Felbatol Increased risk of QT interval prolongation Details Selpercatinib Fentanyl Transdermal Patch Duragesic® Increased substrate exposure and an increased risk for adverse effects Details Selpercatinib Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Selpercatinib Flecainide Tambocor® Increased risk of QT interval prolongation Details Selpercatinib Foscarnet Injection Foscavir Increased risk of QT interval prolongation Details Selpercatinib Fostemsavir Rukobia Increased risk of torsade de pointes Details Selpercatinib Galantamine Razadyne Increased risk of QT interval prolongation Details Selpercatinib Gatifloxacin Ophthalmic Zymar® Increased risk of QT interval prolongation Details Selpercatinib Gemifloxacin Factive Increased risk of QT interval prolongation Details Selpercatinib Glasdegib Daurismo Increased risk of QT interval prolongation Details Selpercatinib Goserelin Implant Zoladex Increased risk of QT interval prolongation Details Selpercatinib Granisetron Transdermal Patch Sancuso Increased risk of QT interval prolongation Details Selpercatinib Granisetron Injection Granisol Increased risk of QT interval prolongation Details Selpercatinib Histrelin Implant Supprelin Increased risk of QT interval prolongation Details Selpercatinib Hydroxychloroquine Plaquenil Increased risk of QT interval prolongation Details Selpercatinib Inotuzumab Ozogamicin Injection Besponsa Increased risk of QT interval prolongation Details Selpercatinib Ivabradine Corlanor Increased risk of QT interval prolongation Details Selpercatinib Lansoprazole Prevacid Reduced selpercatinib exposure and reduced anti-tumor activity Details Selpercatinib Lefamulin Xenleta Increased selpercatinib exposure and an increased risk of QT interval prolongation Details Selpercatinib Lenacapavir Injection Sunlenca Increased selpercatinib exposure and an increased risk of QT interval prolongation Details Selpercatinib Lenacapavir Oral Sunlenca Increased selpercatinib exposure and an increased risk of QT interval prolongation Details Selpercatinib Lenvatinib Lenvima Increased risk of QT interval prolongation Details Selpercatinib Letermovir Injection Prevymis Increased selpercatinib exposure and an increased risk of QT interval prolongation Details Selpercatinib Levofloxacin Levaquin Increased risk of QT interval prolongation Details Selpercatinib Levofloxacin Injection Levaquin Increased risk of QT interval prolongation Details Selpercatinib Loperamide Diamode Increased loperamide exposure, an increased risk of loperamide-related adverse effects and an increased risk of QT interval prolon... Details Selpercatinib Mefloquine Lariam® Increased risk of QT interval prolongation Details Selpercatinib Methylergonovine Methergine Increased methylergonovine exposure Details Selpercatinib Metronidazole Flagyl Increased risk of QT interval prolongation Details Selpercatinib Metronidazole Injection Flagyl Increased risk of QT interval prolongation Details Selpercatinib Metronidazole Topical MetroCream® Increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.